1003 related articles for article (PubMed ID: 11417997)
1. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
[TBL] [Abstract][Full Text] [Related]
2. Acceleration of mouse mammary tumor virus-induced murine mammary tumorigenesis by a p53 172H transgene: influence of FVB background on tumor latency and identification of novel sites of proviral insertion.
Chatterjee G; Rosner A; Han Y; Zelazny ET; Li B; Cardiff RD; Perkins AS
Am J Pathol; 2002 Dec; 161(6):2241-53. PubMed ID: 12466138
[TBL] [Abstract][Full Text] [Related]
3. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.
D'Amico M; Wu K; Di Vizio D; Reutens AT; Stahl M; Fu M; Albanese C; Russell RG; Muller WJ; White M; Negassa A; Lee HW; DePinho RA; Pestell RG
Cancer Res; 2003 Jun; 63(12):3395-402. PubMed ID: 12810676
[TBL] [Abstract][Full Text] [Related]
4. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability.
McCormack SJ; Weaver Z; Deming S; Natarajan G; Torri J; Johnson MD; Liyanage M; Ried T; Dickson RB
Oncogene; 1998 May; 16(21):2755-66. PubMed ID: 9652742
[TBL] [Abstract][Full Text] [Related]
5. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice.
Elson A; Deng C; Campos-Torres J; Donehower LA; Leder P
Oncogene; 1995 Jul; 11(1):181-90. PubMed ID: 7624126
[TBL] [Abstract][Full Text] [Related]
6. Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice.
Backlund MG; Trasti SL; Backlund DC; Cressman VL; Godfrey V; Koller BH
Cancer Res; 2001 Sep; 61(17):6577-82. PubMed ID: 11522657
[TBL] [Abstract][Full Text] [Related]
7. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
8. neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice.
Li B; Rosen JM; McMenamin-Balano J; Muller WJ; Perkins AS
Mol Cell Biol; 1997 Jun; 17(6):3155-63. PubMed ID: 9154814
[TBL] [Abstract][Full Text] [Related]
9. A transgenic mouse model for mammary carcinogenesis.
Li B; Murphy KL; Laucirica R; Kittrell F; Medina D; Rosen JM
Oncogene; 1998 Feb; 16(8):997-1007. PubMed ID: 9519874
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice.
Zinser GM; Welsh J
Carcinogenesis; 2004 Dec; 25(12):2361-72. PubMed ID: 15333467
[TBL] [Abstract][Full Text] [Related]
11. Germ-line expression of an oncogenic erbB2 allele confers resistance to erbB2-induced mammary tumorigenesis.
Andrechek ER; Hardy WR; Laing MA; Muller WJ
Proc Natl Acad Sci U S A; 2004 Apr; 101(14):4984-9. PubMed ID: 15051890
[TBL] [Abstract][Full Text] [Related]
12. p27Kip1 repression of ErbB2-induced mammary tumor growth in transgenic mice involves Skp2 and Wnt/beta-catenin signaling.
Hulit J; Lee RJ; Li Z; Wang C; Katiyar S; Yang J; Quong AA; Wu K; Albanese C; Russell R; Di Vizio D; Koff A; Thummala S; Zhang H; Harrell J; Sun H; Muller WJ; Inghirami G; Lisanti MP; Pestell RG
Cancer Res; 2006 Sep; 66(17):8529-41. PubMed ID: 16951165
[TBL] [Abstract][Full Text] [Related]
13. Lack of ductal development in the absence of functional estrogen receptor alpha delays mammary tumor formation induced by transgenic expression of ErbB2/neu.
Hewitt SC; Bocchinfuso WP; Zhai J; Harrell C; Koonce L; Clark J; Myers P; Korach KS
Cancer Res; 2002 May; 62(10):2798-805. PubMed ID: 12019156
[TBL] [Abstract][Full Text] [Related]
14. Genetic instability favoring transversions associated with ErbB2-induced mammary tumorigenesis.
Liu S; Liu W; Jakubczak JL; Erexson GL; Tindall KR; Chan R; Muller WJ; Adhya S; Garges S; Merlino G
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3770-5. PubMed ID: 11867754
[TBL] [Abstract][Full Text] [Related]
15. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis.
Vaillant F; Asselin-Labat ML; Shackleton M; Forrest NC; Lindeman GJ; Visvader JE
Cancer Res; 2008 Oct; 68(19):7711-7. PubMed ID: 18829523
[TBL] [Abstract][Full Text] [Related]
16. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis.
Lin SC; Lee KF; Nikitin AY; Hilsenbeck SG; Cardiff RD; Li A; Kang KW; Frank SA; Lee WH; Lee EY
Cancer Res; 2004 May; 64(10):3525-32. PubMed ID: 15150107
[TBL] [Abstract][Full Text] [Related]
17. Parity-induced mammary epithelial cells facilitate tumorigenesis in MMTV-neu transgenic mice.
Henry MD; Triplett AA; Oh KB; Smith GH; Wagner KU
Oncogene; 2004 Sep; 23(41):6980-5. PubMed ID: 15286714
[TBL] [Abstract][Full Text] [Related]
18. Selection for loss of p53 function in T-cell lymphomagenesis is alleviated by Moloney murine leukemia virus infection in myc transgenic mice.
Baxter EW; Blyth K; Cameron ER; Neil JC
J Virol; 2001 Oct; 75(20):9790-8. PubMed ID: 11559812
[TBL] [Abstract][Full Text] [Related]
19. Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types.
Cadieux C; Kedinger V; Yao L; Vadnais C; Drossos M; Paquet M; Nepveu A
Cancer Res; 2009 Sep; 69(18):7188-97. PubMed ID: 19738070
[TBL] [Abstract][Full Text] [Related]
20. A recurring pattern of chromosomal aberrations in mammary gland tumors of MMTV-cmyc transgenic mice.
Weaver ZA; McCormack SJ; Liyanage M; du Manoir S; Coleman A; Schröck E; Dickson RB; Ried T
Genes Chromosomes Cancer; 1999 Jul; 25(3):251-60. PubMed ID: 10379871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
